Although the incidence of breast cancer in some Western countries has fallen recently, its incidence still is increasing in Asia.[@b1],[@b2] Furthermore, the survival rate among patients with breast cancer in Asia is approximately half that of patients in Western countries.[@b2],[@b3] These observations are driving interest in gaining a better understanding of breast cancer in Asia.

Studies from Western countries indicate that breast cancer survival is low in patients with tumors that over express the human epidermal growth factor receptor-related gene *ErbB2* (*c-ErbB2*, *HER2*, or *neu*).[@b4],[@b5] Tumors that over express *ErbB2* are more likely to recur[@b4],[@b5] and are relatively resistant to many treatments.[@b4] Two recently developed treatments that specifically target ErbB2, trastuzumab and lapatinib, are effective either alone or with chemotherapy in reducing tumor recurrence and mortality in patients with ErbB2-positive breast cancer.[@b6]

Given the increasing incidence of breast cancer in Asia and the clinical consequences of ErbB2-positive breast cancer, insight into the prevalence of ErbB2-positive tumors in Asia is important. Recently, 2 large studies of breast cancer registry data in the United States reported that women of Asian descent were more likely to have ErbB2-positive tumors than Caucasian women,[@b7],[@b8] suggesting possible racial differences. Whether the prevalence of ErbB2-positive breast cancer differs between Asian and Western countries requires clarification. A higher prevalence of ErbB2-positivity may be 1 of several factors contributing to the lower survival rate of Asian breast cancer patients.

Because ErbB2 status is assessed by different methods (by immunohistochemistry \[IHC\] or, less commonly, by fluorescence in situ hybridization \[FISH\][@b9]), it is also important to know how ErbB2 is assessed within different Asian countries. The accurate estimation of the prevalence of ErbB2-positive tumors in Asia has been hindered by variability in both the availability of assessment methods and the definition of ErbB2 positivity. In addition, data on ErbB2 positivity in Asia are limited in the literature that can be searched electronically (eg, in the MEDLINE database).

To gain insight into the prevalence and assessment of ErbB2-positive breast cancer in Asia through a literature survey, we formed the Early Breast Cancer Working Group (EBCWG). Because we anticipated that it would be a challenge to find data on ErbB2 prevalence in Asia, we also engaged with our peers who were familiar with relevant research in our countries. The objectives of our literature survey were to summarize the reported prevalence of ErbB2-positive breast cancer in 7 Asian countries and to examine the ErbB2 assessment methods used in these countries.

MATERIALS AND METHODS
=====================

Literature Search Strategy
--------------------------

After the initial EBCWG meeting, we conducted separate literature searches for our respective countries (India, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand). We obtained relevant literature from searches of the MEDLINE database using PubMed (2000 to September 2008) with the search terms (ErbB2 OR HER2 OR ErbB-2 OR HER-2) AND "breast cancer" AND (country of interest). We also searched, either electronically or by hand, local language journals and the proceedings of local and international oncology conferences, and we consulted with our professional networks for access to results from recent studies. Because the availability and quality of ErbB2 assessment in Asian clinics increased after the approval of trastuzumab in 2000, we limited our searches to studies that were published during or after 2000.

Study Selection Criteria
------------------------

We selected studies that reported the results of ErbB2 assessment by IHC, FISH, or both for further review. To focus on clinical ErbB2 assessment in our countries, we excluded studies of Asian patients who were living in Western countries and studies that reported serum, messenger RNA, or cell line ErbB2 data. For each country, we selected up to 5 studies for detailed review. Preference was given to studies that had large sample sizes, multicenter studies, and studies that were published in higher impact factor journals.

Data Analysis
-------------

The EBCWG met again to analyze data from the selected studies. We divided the ErbB2 prevalence data from the studies into 3 categories based on the testing and grading methods used for assessment: 1) IHC combined or not specified, ie, IHC with intermediate (IHC2+) and strong (IHC3+) staining combined or IHC with no grading method specified; 2) IHC3+ only; and 3) FISH. Then, we calculated the median and mean (±standard deviation) prevalence of ErbB2-positive tumors in each category.

We hypothesized that lower income countries may report higher ErbB2+ prevalence rates because of the limited availability of robust, but expensive, assay methods (eg, FISH). We used a 2-sample *t* test (assuming unequal variances) to compare differences between low/middle-income countries and high-income countries in the reported ErbB2+ prevalence rates assessed with IHC2+/IHC3+ combined or not specified, IHC3+ only, or FISH. Countries were classified as low, middle, or high income based on the 2007 World Bank income classification (available at: <http://data.worldbank.org/about/country-classifications/a-short-history> accessed July 23, 2010).

RESULTS
=======

Summary of Selected Literature
------------------------------

We selected 22 studies (see [Table 1](#tbl1){ref-type="table"}), including 17 publications[@b10] and 5 conference abstracts,[@b27] for further review. For Malaysia[@b30],[@b31] and the Philippines,[@b29] only conference abstracts met our selection criteria.

###### 

Description of 22 Studies Reporting Human Epidermal Growth Factor Receptor-Related Gene 2-Positive Breast Cancer in Asia

                                                                            Sampling                           Patients (%)                                                                                                                                                                                                                                                                   
  ------------------------------------------------------------------------- ---------------------------------- --------------------------------------------------------------------------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  **India**                                                                                                                                                                                                                                                                                                                                                                                   
   Bhamrah 2008[@b27]; observational                                        210                                All India Institute of Medical Sciences                                     NR          NR                                                                                                                                                                                     NR
   Meenakshi 2003[@b17]; prospective, observational                         127                                Cancer Institute                                                            NR          NR                                                                                                                                                                                     NR
  **Korea**                                                                                                                                                                                                                                                                                                                                                                                   
   Kim 2006[@b14]; retrospective, observational                             776                                Asan Medical Center                                                         1993-1998   Mean, 47.4 y; range, 24-88 y                                                                                                                                                           Stage: I, 182 (23.5); II, 336 (47.2); III, 225 (29); IV, 3 (0.4)
   Korean Breast Cancer Society, 2006[@b24]; retrospective, observational   Total, 9668; ErbB2- tested, 4318   Medical schools, 39; hospitals, 27; private clinics, 7                      2004        Age known: 8376; median, 47 y; ≤29 y, 157 (1.9); 30-39 y, 1409 (16.8); 40-49 y, 3452 (41.2); 50-59 y, 1987 (23.7); 60-69 y, 1017 (12.1); ≥70 y, 354 (4.2)                              Total assessed, 5301 (100); Stage: 0, 508 (9.6); I, 1889 (35.6); II, 2062 (38.9); III, 772 (14.6); IV, 70 (1.3)
   Park 2003[@b19]; prospective, observational                              188                                University Sanggye Paik Hospital                                            NR          NR                                                                                                                                                                                     Histologic grade[b](#tf1-2){ref-type="table-fn"}: 1, 22 (11.7); 2. 83 (44.1); 3. 73 (38.8); unknown: 10 (5.3)
   Park & Han 2004[@b18]; observational                                     Samples in TMA, 132-261            Inje University Sanggye Paik Hospital                                       NR          NR                                                                                                                                                                                     NR
   Shin 2006[@b22]; retrospective, observational                            Total, 4063; ErbB2- tested, 2196   Seoul National Universiti Hospital                                          1981-2002   Median, 46 y; ≤29 y, 163 (4); 30-39 y, 983 (24.2); 40-49 y, 1572 (38.7); 50-59 y, 921 (22.7); 60-69 y, 334 (8.2); ≥70 y, 79 (1.9); unknown, 16 (0.4)[c](#tf1-3){ref-type="table-fn"}   Total assessed, 3761 (100); Stage: 0, 175 (4.7); I, 1042 (27.7); II, 1652 (43.9); III, 726 (19.3); IV, 166 (4.4)
  **Malaysia**                                                                                                                                                                                                                                                                                                                                                                                
   Shahrun 2008[@b30]; retrospective, observational                         300                                International Islamic University Malaysia; Universiti Kebangsaan Malaysia   2003-2007   NR                                                                                                                                                                                     NR
   Tan &Yip 2008[@b31]; prospective, observational                          393                                University Malaya Medical Center                                            2007        \<40 y (12); ≥40 y (88)                                                                                                                                                                Stage: 0, 11 (2.7); I, 98 (24.8); II, 189 (48.2); III, 61 (15.5); IV, 34 (8.7)
  **Singapore**                                                                                                                                                                                                                                                                                                                                                                               
   Fernandopulle 2006[@b12]; retrospective, observational                   112                                Singapore General Hospital                                                  1993-2004   All, ≤35 y; mean, 29.1 y; median, 30 y; range, 19-35 y                                                                                                                                 Histologic grade[d](#tf1-4){ref-type="table-fn"}: 1, 7 (6.3); 2, 24 (21.4); 3, 54 (48.2); unknown, 27 (24.1)
   Selvarajan 2006[@b20]; retrospective, observational                      184                                Singapore General Hospital                                                  1998-2002   NR                                                                                                                                                                                     NR
   Selvarajan 2006[@b21]; retrospective, observational                      321                                Singapore General Hospital                                                  1998-2002   ≤50 y; 134 (41.7); \>50 y, 181 (56.4); unknown, 6 (1.9)                                                                                                                                Stage: I, 68 (21.2); II, 102 (61.8); III, 23 (13.9); IV, 5 (3)
   Tan 2008[@b23]; retrospective, observational                             165                                National Cancer Centre Tissue Repository                                    2000-2004   Mean±SD, 56±12 y; range, 30-79 y; ≤54 y, 82 (49.7); \>54 y, 83 (50.3)                                                                                                                  Stage: I, 36 (21.8); II, 192 (59.8); III, 28 (8.7); IV, 7 (2.2); unknown, 26 (8.1)[e](#tf1-5){ref-type="table-fn"}
   Zhang 2003[@b26]; retrospective, observational                           97                                 National University Hospital                                                NR          NR                                                                                                                                                                                     Histologic grade[f](#tf1-6){ref-type="table-fn"}: 1, 9 (9.3); 2, 34 (35.1); 3, 44 (45.4); unknown, 10 (10.3)
  **Taiwan**                                                                                                                                                                                                                                                                                                                                                                                  
   Chen 2008[@b11]; open label, phase 2 trial                               63                                 Chang Gung Memorial Hospital                                                2002-2005   Median, 46 y; range, 29-69 y                                                                                                                                                           Tumor classification: T2, 25 (39.7); T3, 32 (50.8); T4, 6 (9.5)
   Huang 2008[@b13]; prospective pilot trial                                192                                Kaohsiung Medical University Hospital                                       2003-2005   Median±SD, 48.9±9.6 y; \<50 y, 112 (58.3); ≥50 y, 80 (41.7)                                                                                                                            Stage: II, 160 (83.3); III, 32 (16.7)
   Lin 2007[@b16]; Phase 2 randomized controlled trial                      101                                Chang Gung Memorial Hospital                                                2000-2002   Median, 48 y; range, 25-70 y                                                                                                                                                           All stage IV
   Lin 2009[@b15]; prospective, observational                               1028                               National Taiwan University Hospital                                         2004-2006   Median, 50 y; range, 23-88 y                                                                                                                                                           Stage: I, 316 (30.7); II, 417 (45.8); III, 176 (17.1); IV, 52 (5.1); unknown, 13 (1.3)
   Tsai 2001[@b25]; retrospective, observational                            167                                Kaohsiung Medical University Hospital                                       1990-1999   Mean age: Familial, 47.8 y, n=56; nonfamilial, 50.1 y, n=111                                                                                                                           Histologic grade[g](#tf1-7){ref-type="table-fn"}: 1, 13 (7.8); 2, 51 (30.5); 3, 63 (37.7); unknown, 40 (24)
  **Thailand**                                                                                                                                                                                                                                                                                                                                                                                
   Chearskul 2001[@b10]; retrospective, observational                       506                                Siriraj Hospital                                                            1992-2000   Mean age, 50.8 y; range, 24-89 y; ≤50 y, 246 (48.6); \>50 y, 255 (50.4); unknown, 5 (1)                                                                                                I, 50 (9.9); II, 366 (72.3); III, 60 (11.9); IV, 5 (1); unknown, 25 (4.9)
   Moohamad 2008[@b28]; retrospective, observational                        442                                Phramongkutklao Hospital                                                    2003-2006   NR                                                                                                                                                                                     NR
  **The Philippines**                                                                                                                                                                                                                                                                                                                                                                         
   Sanchez 2007[@b29]; retrospective, observational                         Total, 5307; ErbB2- tested, 2333   St. Luke\'s Medical Center                                                  1994-2004   NR                                                                                                                                                                                     NR

NR indicates not reported; ErbB2, human epidermal growth factor receptor-related gene 2; TMA, tissue microarray; SD, standard deviation.

American Joint Committee on Cancer stages unless otherwise noted.

Nottingham histologic grading system.

Percentages listed were calculated on a total of 4063 patients, as reported by the article. Note: number of patients listed by age in the article actually totals 4068.

United Kingdom National Health System grading system.

The number of patients listed by tumor stage in the article totals 166, not 165. Percentages listed here were calculated based on a total of 165 patients.

Tumor grades were stated in the article, but the grading system was not specified.

Modified Bloom-Richardson grading system.

Patients Assessed for ErbB2
---------------------------

Our selected studies included 24,671 patients, including 14,398 patients (58.4%) who were assessed for ErbB2 (Table [1](#tbl1){ref-type="table"}). The number of patients in each study ranged from 63 patients[@b11] to 9668 patients,[@b24] and the number assessed for ErbB2 ranged from 63 patients[@b11] to 4319 patients.[@b24] The age of patients varied widely (range, 19-89 years) among those studies in which it was reported; however, most patients were in their 40s or 50s. Most patients (10,203 of 13,171 patients; 77.5%) for whom cancer stage was reported had early stage breast cancer (stage 0, n = 694 \[5.3%\]; stage I, n = 3732 \[28.3%\]; stage II, n = 5777 \[43.9%\]).

Prevalence of ErbB2-Positive Breast Cancer
------------------------------------------

The prevalence of ErbB2-positive breast cancer in Asia was influenced by the testing method and grading criteria used ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). Generally, prevalence results were lowest with IHC when positivity was defined as IHC3+, intermediate with FISH, and highest with IHC when positivity was defined as IHC2+ and IHC3+ combined or when positivity was not defined. When the results obtained using any of the assessment methods were examined, the prevalence of ErbB2-positive breast cancer varied widely (range, 6%-65%). When results were limited to those obtained with the more robust methods (IHC3+, FISH), the median prevalence was 19% and 25%, respectively ([Fig. 1](#fig01){ref-type="fig"}). Even with this narrower focus, these results were obtained from 10,076 patients in 5 Asian countries (India, Korea, Singapore, Taiwan, and the Philippines). The least variable results were obtained with the less common assessment method, FISH ([Table 3](#tbl3){ref-type="table"}).

![The median prevalence of human epidermal growth factor receptor-related gene 2 (ErbB2)-positive breast cancer is shown. Solid columns indicate 7 Asian countries; open columns, high-income countries; hatched columns, low-income/middle-income countries. The number of studies and the number of patients are shown within and beneath each column, respectively. IHC indicates immunohistochemistry; FISH, fluorescence in situ hybridization.](cncr0116-5348-f1){#fig01}

###### 

Description of Human Epidermal Growth Factor Receptor-Related Gene 2 (ErbB2) Assessment in 22 Studies Reporting ErbB2-Positive Breast Cancer in Asia

                                                                                                                                                                                                                           Percentage of Patients (No./Total No.)                                                                                                
  ------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------------
  **India**                                                                                                                                                                                                                                                                                                                                                      
   Bhamrah 2008[@b27]                        IHC: antibody, NR                                                                                                                                                             28.6 (60/210)[c](#tf2-3){ref-type="table-fn"},[d](#tf2-4){ref-type="table-fn"}    NR                                                  NR
   Meenakshi 2003[@b17]                      IHC2+, IHC3+: antibody, in-house monoclonal (CIBCgp185)                                                                                                                       25.2 (32/127)                                                                     15.7 (20/127)                                       NR
  **Korea**                                                                                                                                                                                                                                                                                                                                                      
   Kim 2006[@b14]                            IHC3+: ≥10% cells positive; antibody, Dako (Glostrup, Denmark)                                                                                                                NR                                                                                25 (194/776)                                        NR
   Korean Breast Cancer Society 2006[@b24]   IHC2+, IHC3+; antibody: NR                                                                                                                                                    36.9 (1594/4319)                                                                  19.8 (854/4319)                                     NR
   Park 2003[@b19]                           FISH: signal ≥2-fold centromere region of chromosome 17; CISH: gene copy \>4                                                                                                  NR                                                                                NR                                                  24.5 (46/188)
   Park & Han, 2004[@b18]                    IHC2+, IHC3+: antibodies, HercepTest (Dako), rabbit anti-c-ErbB2 (Zymed, South San Francisco, Calif), mouse anti-c-ErbB2 (Zymed); FISH: criteria not reported in English      17.9-22.7 (40/188)[e](#tf2-5){ref-type="table-fn"}                                6.1-14.4 (21/188)[e](#tf2-5){ref-type="table-fn"}   24-28 (73/261)[e](#tf2-5){ref-type="table-fn"},[f](#tf2-6){ref-type="table-fn"}
   Shin 2006[@b22]                           IHC2+, IHC3+: antibody, NR                                                                                                                                                    51.5 (1131/2196)                                                                  NR                                                  NR
  **Malaysia**                                                                                                                                                                                                                                                                                                                                                   
   Shahrun 2008[@b30]                        NR                                                                                                                                                                            44.4 (133/300)[c](#tf2-3){ref-type="table-fn"},[g](#tf2-7){ref-type="table-fn"}   NR                                                  NR
   Tan & Yip, 2008[@b31]                     IHC2+, IHC3+: antibody, Dako                                                                                                                                                  60.6 (238/393)[c](#tf2-3){ref-type="table-fn"}                                    34.5 (136/393)[c](#tf2-3){ref-type="table-fn"}      NR
  **Singapore**                                                                                                                                                                                                                                                                                                                                                  
   Fernandopulle 2006[@b12]                  IHC2+, IHC3+: antibody, rabbit polyclonal (A0485; Dako)                                                                                                                       29.6 (16/54)                                                                      NR                                                  NR
   Selvarajan 2006[@b20]                     IHC2+, IHC3+: antibody, rabbit polyclonal, Dako (A0485; Dako); performed on standard sections and TMA                                                                         21.2 (39/184)                                                                     12.5 (23/184)[h](#tf2-8){ref-type="table-fn"}       NR
   Selvarajan 2006[@b21]                     IHC2+, IHC3+: antibody, rabbit polyclonal (Dako)                                                                                                                              34.3 (110/321)                                                                    NR                                                  NR
   Tan 2008[@b23]                            IHC2+, IHC3+: antibody: SP3, Lab Vision (Thermo Fisher Scientific, Waltham, Mass); FISH: signal ≥2.2-fold centromere region of chromosome 17 (PathVysion, Des Plaines, Ill)   19 (27/142)                                                                       11.3 (16/142)                                       37.9 (55/145)
   Zhang 2003[@b26]                          IHC2+, IHC3+: antibody, HercepTest; FISH: signal ≥2-fold centromere region of chromosome 17 (PathVysion)                                                                      25 (23/92)                                                                        15.2 (14/92)                                        23 (20/87)
  **Taiwan**                                                                                                                                                                                                                                                                                                                                                     
   Chen 2008[@b11]                           IHC3+: antibody, HercepTest                                                                                                                                                   NR                                                                                19 (12/63)                                          NR
   Huang 2008[@b13]                          NR                                                                                                                                                                            64.6 (124/192)[g](#tf2-7){ref-type="table-fn"}                                    NR                                                  NR
   Lin 2007[@b16]                            NR                                                                                                                                                                            27.7 (28/101)[g](#tf2-7){ref-type="table-fn"}                                     NR                                                  NR
   Lin 2009[@b15]                            IHC3+: antibody, polyclonal (Dako); IHC2+: confirmation by FISH (signal ≥2-fold centromere region of chromosome 17; PathVysion)                                               NR                                                                                20.5 (211/1028)[i](#tf2-9){ref-type="table-fn"}     NR
   Tsai 2001[@b25]                           IHC3+: antibody, HercepTest                                                                                                                                                   NR                                                                                41.3 (69/167)                                       NR
  **Thailand**                                                                                                                                                                                                                                                                                                                                                   
   Chearskul 2001[@b10]                      IHC2+: antibody, rabbit polyclonal (Dako)                                                                                                                                     32.2 (163/506)                                                                    NR                                                  NR
   Moohamad 2008[@b28]                       IHC: antibody, NR                                                                                                                                                             17.9 (79/442)[g](#tf2-7){ref-type="table-fn"}                                     NR                                                  NR
  **The Philippines**                                                                                                                                                                                                                                                                                                                                            
   Sanchez 2007[@b29]                        IHC3+: antibody, NR                                                                                                                                                           NR                                                                                20 (466/2333)                                       NR

IHC indicates immunohistochemistry; FISH, fluorescence in situ hybridization; CISH, chromogenic in situ hybridization; TMA, tissue microarray; NR, not reported.

Combined results of IHC2+ and IHC3+ were reported (whether separately or together) unless indicated otherwise.

Results for IHC3+ were reported separately.

The number of ErbB2-positive patients was not stated in study but was calculated from the number assessed and prevalence.

Results are reported as a range.

This study used 3 antibodies; results using the HercepTest are shown.

This study used FISH in 3 separate TMAs; results from the largest sample (N=261) are shown.

IHC results were reported as positive, but criteria were not specified.

Results for standard sections.

Included IHC2+ confirmed by FISH (50 of 211).

###### 

Prevalence of Human Epidermal Growth Factor Receptor-Related Gene 2-Positive Breast Cancer in Asia

                                                                           ErbB2 Assessment Method               
  ------------------------------------------------------------------------ ------------------------- ----------- ----------
  Studies using method, no.[c](#tf3-3){ref-type="table-fn"}                16                        12          4
  ErbB2-positive patients, no./total no.[c](#tf3-3){ref-type="table-fn"}   3837/9767                 2036/9812   194/681
  **ErbB2-positive prevalence, %**                                                                               
   Minimum                                                                 17.9                      6.1         23
   Maximum                                                                 64.6                      41.3        37.9
   Median                                                                  29.1                      19.4        25.3
   Mean±SD                                                                 33.7±14.5                 20.4±9.3    27.9±6.8

ErbB2 indicates human epidermal growth factor receptor-related gene 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; SD, standard deviation.

Either combined IHC2+ and IHC3+ (whether reported separately or together) or IHC results were reported as positive, but criteria were not specified.

Results for IHC3+ were reported separately.

Because some studies used more than 1 ErbB2 assessment method, the apparent total number of studies and patients (ie, the sum of IHC2+/IHC3+, IHC 3+, and FISH shown in this table) is greater than the actual number.

The mean prevalence of ErbB2-positive tumors was similar to the median prevalence for all 3 assessment methods ([Table 3](#tbl3){ref-type="table"}). Omitting the maximum and minimum prevalence values did not change the mean markedly (IHC2+/IHC3+ combined or not specified = 32.6% vs an actual rate of 33.7%; IHC3+ only = 19.4% vs an actual rate of 20.4%).

When prevalence data from high-income (Korea, Singapore, and Taiwan) and low or middle-income (India, Malaysia, Thailand, and the Philippines) countries were compared, there was no significant difference (*P* = .82) in the mean prevalence when positivity was defined as IHC2+/IHC3+ or when the definition was not specified. Similarly, there was no significant difference (*P* = .59) in the mean prevalence when positivity was defined as IHC3+. The similarity in prevalence results between high-income and low or middle-income countries also was apparent from a comparison of the median values for IHC ([Fig. 1](#fig01){ref-type="fig"}). No comparison could be made for studies using FISH, because none of the studies from low or middle-income countries used this method. Among the countries in our survey, only high-income countries (ie, Korea, Singapore, and Taiwan) routinely tested for ErbB2 status and subsidized the cost of trastuzumab for eligible patients ([Table 4](#tbl4){ref-type="table"}).

###### 

Availability of Human Epidermal Growth Factor Receptor-Related Gene 2 (ErbB2) Assessment Methods and ErbB2-Targeted Treatments in 7 Asian Countries

                                 High-Income Countries   Low/Middle-Income Countries                                      
  ------------------------------ ----------------------- ----------------------------- --------- --------- --------- ---- ---------
  **IHC testing**                                                                                                         
   Routine?                      Yes                     Yes                           Yes       Yes       No        No   No
   Standardized?                 Yes                     Yes                           No        No        No        No   Partial
  **FISH testing**                                                                                                        
   Routine?                      Yes                     Yes                           Yes       No        No        No   No
   Standardized?                 Partial                 Partial                       Partial   No        No        No   Partial
  **ErbB2-targeted treatment**                                                                                            
   Subsidized?                   Yes                     Yes                           Yes       Partial   Partial   No   Partial

IHC indicates immunohistochemistry; FISH, fluorescence in situ hybridization.

ErbB2 Assessment Methods
------------------------

The most common ErbB2 assessment method was IHC, which was used in 21 of 22 studies (95.5%). Although 12 studies provided the name and/or supplier of the antibody used, 7 studies (including the 5 conference abstracts) did not specify either. The most commonly used antibodies were from Dako (Glostrup, Denmark), including 4 studies that used the HercepTest (Dako), 2 studies that used the A0485 rabbit polyclonal antibody, and 4 studies that used unspecified Dako antibodies. Only 4 studies[@b18],[@b19],[@b26],[@b31] from 2 countries (Korea and Singapore) used FISH to assess ErbB2, whereas 1 study from Taiwan[@b15] used FISH to confirm ErbB2 positivity in tumors with IHC2+ staining.

DISCUSSION
==========

On the basis of the ErbB2 assessment results from 14,398 patients in 7 Asian countries, our literature survey indicated that the reported prevalence of ErbB2-positive breast cancer has varied from 6% to 65%. However, when ErbB2 was assessed robustly using IHC3+ or FISH, the median prevalence, based on the results from 10,076 Asian patients in 5 countries, was 19% with IHC3+ and 25% with FISH. These prevalence results are similar to those in Western countries.[@b4],[@b5] Because ErbB2 status is predictive for both prognosis and therapeutic response, knowledge of a patient\'s ErbB2 status could help physicians identify the most appropriate treatment. Our survey indicates that up to 1 in 4 Asian patients with breast cancer potentially could benefit from ErbB2-targeted treatment. In addition, the variability in ErbB2 assessment methods evident from our survey highlights the need for Asian countries to use a standard, reliable method to assess ErbB2. Enhanced ErbB2 assessment methods would enable us to further refine our understanding of the prevalence of ErbB2-positive breast cancer in Asia.

To the best of our knowledge, this is the first survey of ErbB2-positivity results obtained from a large sample of patients to indicate that the prevalence of ErbB2-positive breast cancer in Asia is similar to that in Western countries (range, 18%-25%).[@b4],[@b5] Notably, this finding is based on Asian data that were obtained using the more robust assessment methods, IHC3+ and FISH.[@b32],[@b33] Because the prevalence of ErbB2-positive tumors is not apparently higher in Asia, alternative reasons for the low breast cancer survival rate should be explored. Possible reasons include advanced stage at diagnosis[@b3],[@b34]; younger patients (aged \<50 years; associated with more aggressive tumors)[@b3],[@b35]; higher prevalence of estrogen or progesterone receptor-negative tumors, which are less responsive to endocrine therapies[@b3],[@b36]; and the cost and availability of treatments, including those that target ErbB2.[@b3],[@b34]

In our survey, we observed considerable variability in ErbB2 assessment methods. The most common method was IHC; however, many factors contribute to variability in IHC results, including the antibody used[@b4],[@b9] and the grading criteria.[@b9] The relatively small size of many Asian laboratories also may have contributed to the variability we observed. Indeed, the concordance in IHC results between small, local laboratories and high-throughput, central laboratories can be unacceptably low.[@b9]

We also observed great variability in how IHC results were reported. Many studies reported both IHC2+ and IHC3+ staining separately. However, although some categorized both IHC2+ and IHC3+ staining as positive,[@b12],[@b17],[@b18],[@b20],[@b21] others categorized only IHC3+ staining as positive.[@b11],[@b14],[@b25],[@b29] Recent guidelines that were published jointly by the American Society for Clinical Oncology and the College of American Pathologists (ASCO/CAP) recommend reporting IHC2+ and IHC3+ staining separately and confirming the ErbB2 status of IHC2+ tumors by FISH.[@b9] These recommendations are based on the poor concordance between IHC2+ staining and gene amplification by FISH.[@b4],[@b9],[@b32],[@b33] Among the studies in our survey, only 5 used FISH to determine or confirm ErbB2 status.[@b15],[@b18],[@b19],[@b26],[@b31] Not surprisingly, these studies were conducted in Korea, Singapore, and Taiwan, countries that are able to fund this more expensive method.

Despite the apparent similarity in the prevalence of ErbB2-positive breast cancer in Asian and Western countries, many Asian patients will not have the same opportunity as Western patients to receive ErbB2-targeted treatment. ErbB2-positive tumors respond well to ErbB2-targeted treatments,[@b6] but these treatments are expensive and, thus, may not be available to many Asian patients ([Table 4](#tbl4){ref-type="table"}). Without subsidies, many Asian patients with ErbB2-positive breast cancer may not be able to afford ErbB2-targeted treatments, which in turn, may reduce the incentive for ErbB2 assessment. Individual countries need to weigh the costs of ErbB2 assessment and treatment with the potential benefit for patients. Because our survey suggests that the prevalence of ErbB2-positive tumors is not related to country income level, at least there is no epidemiologic justification for restricting ErbB2 assessment and treatment in lower income countries.

Worldwide standardization of ErbB2 assessment is an important goal not only for obtaining unbiased data on the prevalence of ErbB2-positive breast cancer but also to ensure that patients receive the most appropriate treatment. Ideally, a standardized assessment method would adhere to the ASCO/CAP guidelines.[@b9] However, we must emphasize that the stringent ASCO/CAP recommendations are not practical in many lower income countries.[@b9] We believe that greater standardization of ErbB2 assessment is particularly needed in the low or middle-income countries that were included in our study (India, Malaysia, Thailand, and the Philippines)([Table 4](#tbl4){ref-type="table"}). The Breast Health Global Initiative recognizes that the costs of ErbB2 assessment, especially FISH, and ErbB2-targeted therapies are "prohibitively expensive" in countries with limited resources.[@b37] Because ErbB2 assessment is not routine in many Asian countries, it would be beneficial, if not prudent, to provide pathologists with a standardized protocol and regular validation testing. Given the impact of pathologist and laboratory experience on ErbB2 results, smaller Asian countries also might consider establishing a central laboratory for national ErbB2 assessment.

Our survey has strengths and limitations. We believe that our conclusions regarding the prevalence of ErbB2-positive breast cancer and ErbB2 assessment methods in Asia are strengthened by the use of data from 22 studies involving more than 14,000 patients in 7 Asian countries that vary in ethnicity, size, and economic status. In addition, as experts in our respective countries, we were able to include data from local language journals and conferences, which are not readily available from the MEDLINE database. However, we recognize that our survey does have limitations. We did not perform a comprehensive, systematic literature review; rather, we chose to limit the number of studies we included from each country to avoid over-representation of larger, wealthier countries with more available data. For some countries in our survey, the only available studies that met our criteria were published as conference abstracts. We chose to include these studies, despite their preliminary nature, to examine the current state of ErbB2 assessment and prevalence in these countries. Although data for Malaysia were limited at the time of our survey, the prevalence of ErbB2 positivity reported in a recent article is consistent with the prevalence we obtained.[@b38] Also, although our survey included data from 7 countries, we did not include data from all Asian countries. Notably, we did not include data from Japan or China. However, our prevalence results are consistent with those reported in recent studies from Japan;[@b39],[@b40] (range, 11%-27%) and China[@b41](20%). Finally, any literature survey is retrospective in nature and, as we observed, is subject to data heterogeneity. Among other factors, referral bias may have affected the prevalence reported by some researchers, particularly those from specialist centers. Whether the data in our selected studies are representative of the wider population of breast cancer patients in these countries cannot be determined until further studies are conducted. Nevertheless, as regional breast cancer experts, we believe the available data, although limited, are consistent with our clinical experience.

In summary, data on the prevalence of ErbB2-positive breast cancer in Asia are limited. Nevertheless, our survey, based on data from 14,398 patients in 7 Asian countries, indicates that the reported prevalence of ErbB2-positive breast cancer has varied widely from 6% to 65%. However, when ErbB2 status was assessed robustly, the median prevalence, based on data from 10,076 patients in 5 Asian countries, was 19% (IHC3+) or 25% (FISH), similar to that in the West. Because ErbB2 status is predictive of both prognosis and responsiveness to targeted therapies, Asian countries should work toward standardization of ErbB2 assessment.
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